title: Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
abstract: B cell lymphoproliferative disorders arising in organ transplant recipients (B cell posttransplant lymphoproliferative disorders [PTLD]) are generally associated with EBV. In previous reports, B cell PTLD were shown to express the full pattern of EBV latent genes, as in vitro-established lymphoblastoid cell lines. Although viral linear DNA was detected in 40% of lymphoproliferative disorders from immunocompromised hosts, immunophenotypic studies failed to detect late EBV replicative antigens. The aim of this study was to investigate the relationship of EBV latent gene expression in B cell PTLD to morphology, clonality, and immunophenotype, and to examine the replicative state of EBV in malignant cells. For this purpose, 9 cases of EBV-related B cell PTLD were analyzed. Immunoglobulin gene rearrangements were detected by Southern blot analysis. The presence of EBV was assessed by Southern blot and by in situ hybridization. B cell differentiation antigens, adhesion and activation molecules, and EBV latent and replicative gene expression were studied using immunohistochemistry techniques. We demonstrated that EBV-related B cell PTLD exhibited varying patterns of latent viral gene expression. Higher levels of adhesion molecules were detected in latent membrane protein 1 (LMP1) or LMP1 plus EBV nuclear antigen 2 (EBNA2)-positive tumors than in LMP1 and EBNA2-negative tumors. In contrast, there was no relationship between CD21 and CD23 expression and latent EBV phenotype. Activation of the EBV replicative cycle was highlighted by BamHI Z left frame 1 expression in 5 of 9 cases. Less frequent expression of late viral proteins suggested that the initiation of the EBV lytic cycle might not always lead to virions production.
authors.affiliation: Department of Hematology, Hôpital Pitié Salpétrière, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Rea
authors.forename: C
authors.initials: C
authors.lastname: Fourcade
authors.forename: V
authors.initials: V
authors.lastname: Leblond
authors.forename: M
authors.initials: M
authors.lastname: Rowe
authors.forename: I
authors.initials: I
authors.lastname: Joab
authors.forename: L
authors.initials: L
authors.lastname: Edelman
authors.forename: M O
authors.initials: MO
authors.lastname: Bitker
authors.forename: I
authors.initials: I
authors.lastname: Gandjbakhch
authors.forename: C
authors.initials: C
authors.lastname: Suberbielle
authors.forename: J P
authors.initials: JP
authors.lastname: Farcet
mesh_terms: D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000382:microbiology*; D015815:Cell Adhesion Molecules / Q000502:physiology; D005260:Female; D015967:Gene Expression Regulation, Viral; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000502:physiology; D006801:Humans; D016130:Immunophenotyping; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D010641:Phenotype; D017735:Virus Latency / Q000235:genetics; D014779:Virus Replication / Q000235:genetics
chemical_list: D015815:Cell Adhesion Molecules